Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Lebanon Healthcare Journal.
Press releases published on May 15, 2025
GT Biopharma Appoints New Member to its Board of Directors
GlobeNewswire
·
May 15, 2025
SAN FRANCISCO, CALIFORNIA, May 15, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer ( …
Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform
GlobeNewswire
·
May 15, 2025
WARSAW, Poland, May 15, 2025 (GLOBE NEWSWIRE) -- Member States are nearing the end of discussions on EU pharmaceutical reform to ensure affordable medicines and support EU manufacturing in Europe. This will enhance the Union’s strategic resilience and …
Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum
GlobeNewswire
·
May 15, 2025
DURHAM, NC and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ("MRI") of the lungs, will be featured at …
Veri Medtech (VRHI) Reaches $100 Million Revenue Milestone
GlobeNewswire
·
May 15, 2025
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Veri Medtech Holdings, Inc. (Stock Ticker Symbol: “VRHI”) ("Veri Medtech"), healthcare technology platform, announced today that $3,308,297 in revenue was generated during the first quarter of 2025, with an …
CorMedix Inc. to Participate in the RBC Global Healthcare Conference
GlobeNewswire
·
May 15, 2025
BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the RBC …
Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology
GlobeNewswire
·
May 15, 2025
Patent strengthens Autonomix’s intellectual property position in the nerve-mapping and denervation space, supporting the Company’s broader mission to advance minimally invasive, nerve-focused therapeutics Company continues to expand its growing global …
Longevity Health Holdings Announces Business Updates
GlobeNewswire
·
May 15, 2025
PITTSBURGH and GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on extending human longevity and healthy aging through technologically innovative and clinically proven products in …
Lifeward Ltd. Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 15, 2025
U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter …
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
GlobeNewswire
·
May 15, 2025
-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at the ASGCT Annual Meeting -- BRISBANE, …
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
GlobeNewswire
·
May 15, 2025
Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog Evidence suggests sustained inflammation plays a central role in the …
OPKO Health to Participate in Two Upcoming Investor Conferences
GlobeNewswire
·
May 15, 2025
MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in two investor conferences over the coming weeks. H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in …
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
·
May 15, 2025
IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, …
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
GlobeNewswire
·
May 15, 2025
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic …
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
GlobeNewswire
·
May 15, 2025
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May …
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
GlobeNewswire
·
May 15, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates …
Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
GlobeNewswire
·
May 15, 2025
Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC) Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including 43% with PD-L1 below 1 (TPS <1%), who represent an area …
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
—Reported Positive 48-Week Data from SPRING Trial—Nebokitug Treatment in PSC Patients with Moderate/Advanced Disease Resulted in Continued Improvements across Key Biomarkers of Liver Injury, Inflammation and Fibrosis— —Aligned with FDA on Pathway to …
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update
GlobeNewswire
·
May 15, 2025
NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended …
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
GlobeNewswire
·
May 15, 2025
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised the Company to submit pivotal Part B trial protocol and associated statistical analysis plan as an …